Albumedix

Sartorius, through its subgroup Sartorius Stedim Biotech, acquired Albumedix in 2022. The company provides recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies.